Market closed
TransMedics Group/$TMDX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About TransMedics Group
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
Ticker
$TMDX
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
584
Website
TMDX Metrics
BasicAdvanced
$2.4B
76.78
$0.94
1.99
-
Price and volume
Market cap
$2.4B
Beta
1.99
52-week high
$177.37
52-week low
$55.00
Average daily volume
2.1M
Financial strength
Current ratio
8.201
Quick ratio
6.998
Long term debt to equity
245.619
Total debt to equity
246.83
Interest coverage (TTM)
2.32%
Management effectiveness
Return on assets (TTM)
2.84%
Return on equity (TTM)
19.41%
Valuation
Price to earnings (TTM)
76.778
Price to revenue (TTM)
5.918
Price to book
11.5
Price to tangible book (TTM)
12.31
Price to free cash flow (TTM)
-19.698
Growth
Revenue change (TTM)
109.09%
Earnings per share change (TTM)
-184.77%
3-year revenue growth (CAGR)
142.23%
3-year earnings per share growth (CAGR)
-12.07%
What the Analysts think about TMDX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for TransMedics Group stock.
TMDX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TMDX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TMDX News
AllArticlesVideos
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 15, 2025 in TransMedics Group, Inc. Lawsuit - TMDX
Accesswire·4 hours ago
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of TransMedics Group
Accesswire·4 hours ago
Class Action Filed Against TransMedics Group, Inc. (TMDX) Seeking Recovery for Investors - Contact Levi & Korsinsky
Accesswire·6 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for TransMedics Group stock?
TransMedics Group (TMDX) has a market cap of $2.4B as of February 23, 2025.
What is the P/E ratio for TransMedics Group stock?
The price to earnings (P/E) ratio for TransMedics Group (TMDX) stock is 76.78 as of February 23, 2025.
Does TransMedics Group stock pay dividends?
No, TransMedics Group (TMDX) stock does not pay dividends to its shareholders as of February 23, 2025.
When is the next TransMedics Group dividend payment date?
TransMedics Group (TMDX) stock does not pay dividends to its shareholders.
What is the beta indicator for TransMedics Group?
TransMedics Group (TMDX) has a beta rating of 1.99. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.